MarketWatch.com - Top Stories

Intel has become a political pawn — but it may not need...

It’s possible that the Trump administration could make some changes to the U.S. ...

Global oil prices on track for weekly gain as U.S. look...

Global benchmark crude prices were poised to post their first weekly gain in a m...

U.S. industrial output picks up — a sign that tariff th...

After being flat for two years, economist see the industrial-production sector s...

How to plan for when you can no longer drive safely

Older adults typically live seven to 10 years longer than they can safely drive.

How to plan for your driving retirement — the transitio...

Older adults typically live seven to 10 years longer than they can safely drive.

SoundHound’s stock sinks as Nvidia sells off stake. Wha...

Nvidia’s latest 13-F also indicates it sold its stake in Serve Robotics, and sha...

Import prices see biggest rise in nine months, but they...

The cost of imports has been pretty tame for the past few years, but they could ...

Treasury yields tumble a second day after surprisingly ...

U.S. government debt rallied for a second day on Friday, after retail sales for ...

Hedge fund giant Bridgewater made a new bet on Tesla. T...

The world’s biggest hedge fund made a fresh bet on EV maker Tesla Inc. late last...

Import prices see biggest rise in nine months, but not ...

The cost of imports are getting more scrutiny

Moderna is counting on its product pipeline to resuscit...

The company hopes to deliver “up to 10 product approvals through 2027.”

Oil prices on track for weekly gain as tariff fears fade

Oil futures rose Friday and were on track to snap a streak of three straight wee...

Treasury yields hold mostly steady ahead of retail-sale...

U.S. Treasury yields were mixed on Friday, but recuperating some ground from a s...

Is the stock market open on Presidents Day? Will the po...

What you need to know about how the Presidents Day holiday affects financial mar...

Moderna looks to pipeline to restore battered stock aft...

COVID-19 vaccine sales topped consensus but RSV sales remain modest

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.